Slumping Stocks: Cempra (NASDAQ:CEMP), Dyax (NASDAQ:DYAX), Scorpio Tankers (NYSE:STNG), Goldcorp (NYSE:GG)

On Thursday, Cempra Inc (NASDAQ:CEMP)’s shares declined -6.72% to $31.49.

Cempra Inc (CEMP) stated financial results for the quarter ended March 31, 2015 and offered an update on recent corporate developments. The company will host a webcast and conference call recently at 4:30 p.m. EDT.

First Quarter 2015 and Recent Corporate Highlights

• In April 2015, investigators presented abstracts and select data from clinical and scientific studies of solithromycin at the European Congress of Clinical Microbiology (ECCMID) in Copenhagen, Denmark. Two studies with Taksta(TM) (fusidic acid) were also presented. Additionally, Cempra made a presentation on solithromycin at the 2015 Pediatric Academic Societies (PAS) Annual Meeting in San Diego. This pediatric study was funded by BARDA (Biomedical Advanced Research Development Authority).

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates comprise solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community attained bacterial pneumonia, in addition to for uncomplicated bacterial urethritis; and Taksta (CEM-102), an antibiotic that has accomplished Phase II clinical trials for refractory bone and joint infections.

Dyax Corp. (NASDAQ:DYAX)’s shares dropped -6.67% to $23.91.

Dyax Corp. (DYAX) declared that executive administration will take part in the following forthcoming investor conferences:

• The Deutsche Bank 40^thAnnual Health Care Conference being held May 6-7, 2015 at The InterContinental Hotel in Boston, MA. The Company will present on Wednesday, May 6 at 4:50 PM (ET).
• The Bank of America Merrill Lynch 2015 Health Care Conference being held May 12-14, 2015 at the Encore at the Wynn in Las Vegas, NV. The Company will present on Wednesday, May 13 at 11:20 AM (PT).

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders.

At the end of Thursday’s trade, Scorpio Tankers Inc. (NYSE:STNG)‘s shares dipped -6.60% to $9.34.

Scorpio Tankers Inc. (STNG) declared that it has priced its formerly declared underwritten public offering of 15 million of its common shares, par value $0.01 per share (the “Common Shares”), at $9.30 per share. The Offering is predictable to close on May 5, 2015. UBS Securities LLC is acting as sole book-running manager in the Offering and Clarksons Platou Securities, Inc. is acting as Joint Lead Manager. Clarksons Capital Markets, LLC, Evercore Group L.L.C., Nomura Securities International, Inc. and Stifel are acting as Senior Co-Managers. The Company has also granted the underwriters a 30-day option to purchase up to 2,250,000 additional Common Shares. Substantially all of the net proceeds of the Offering are predictable to be used to fund a portion of the acquisition costs of additional modern product tankers, which may comprise three LR2 product tankers that the Company presently has options to purchase from an unassociated third party. Any net proceeds of the Offering not used for vessel acquisitions are predictable to be used for general corporate purposes.

Scorpio Tankers Inc., together with its auxiliaries, engages in the seaborne transportation of refined petroleum products and crude oil worldwide. As of March 31, 2015, it owned 67 tankers comprising 11 LR2 tanker, 2 LR1 tankers, 15 Handymax tankers, 39 MR tankers with an average age of 1.1 years; and time charters-in 20 product tankers, counting 5 LR2, 5 LR1, 3 MR, and 7 Handymax tankers.

Goldcorp Inc. (USA) (NYSE:GG), ended its Thursday’s trading session with -9.63% loss, and closed at $18.83.

Goldcorp Inc. (USA) (GG) stated sales1 of 827,500 gold ounces resulting in adjusted operating cash flow1,3 of $366 million for the first quarter of 2015, contrast to adjusted operating cash flow of $281 million for the first quarter of 2014. Adjusted quarterly revenues1 were $1.27 billion, generating adjusted net earnings1,2 of $12 million, or $0.01 per share, contrast to adjusted net earnings of $209 million, or $0.26 per share, for the first quarter of 2014. Stated net loss for the quarter was $87 million, or ($0.11) per share, contrast to net earnings of $98 million, or $0.12 per share, for the first quarter of 2014.

First Quarter 2015 Highlights

• Quarterly gold sales of 827,500 ounces; gold production¹of 724,800 ounces.
• Adjusted revenues of $1.27 billion.
• All-in sustaining costs^1,4of $885 per ounce.
• Adjusted net earnings of $12 million, or $0.01 per share.
• Adjusted operating cash flow of $366 million.

Goldcorp Inc. engages in the acquisition, exploration, development, and operation of precious metal properties in Canada, the United States, Mexico, and Central and South America. DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.